Wichita, Kansas 67214

  • HIV Infections


To compare the uptake of azithromycin in white cells relative to plasma concentrations in HIV-infected patients.

Study summary:

Patients are randomized to receive azithromycin orally or intravenously, with crossover to the alternate treatment after a 21-day wash-out period.


Inclusion Criteria Concurrent Medication: Allowed: - Antiretroviral agents, provided regimen has been stable for at least 1 month. Patients must have: - HIV infection. - CD4 count <= 200 cells/mm3. - No active opportunistic infection (pending discussion with Pfizer Clinician). Prior Medication: Allowed: - Prior antiretroviral agents. Exclusion Criteria Co-existing Condition: Patients with the following symptoms or conditions are excluded: - Active intercurrent illness (pending discussion with the Pfizer Clinician). - Allergies to macrolide antibiotics. - Signs and symptoms of severe illness that would preclude treatment. Patients with the following prior conditions are excluded: - History of clinically significant allergic, hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, or neurological disease. - Clinically important change in baseline status within 4 weeks prior to study entry. - Condition affecting drug absorption (e.g., ulcers, gastrectomy, HIV-associated enteropathies) within 4 weeks prior to study entry. Prior Medication: Excluded: - Investigational drugs including treatment IND drugs within 4 weeks prior to study entry. Known drug or alcohol dependence.



Primary Contact:


Backup Contact:


Location Contact:

Wichita, Kansas 67214
United States

There is no listed contact information for this specific location.

Site Status: N/A

Data Source: ClinicalTrials.gov

Date Processed: June 18, 2021

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.

Click to view Full Listing

This study is not currently recruiting Study Participants on ClinicalConnection.com. The form below is not enabled.